TRAVERE THERAPEUTICS INC. - COMMON STOCK

Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

02 6 2021 08:00:01 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

27 5 2021 16:30:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis

25 5 2021 16:01:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics Reports First Quarter 2021 Financial Results

06 5 2021 16:01:02 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

27 4 2021 16:30:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Report First Quarter 2021 Financial Results

26 4 2021 16:30:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

01 3 2021 16:01:01 提供 Nasdaq GlobeNewswire

Travere Therapeutics Recognizes Rare Disease Day 2021 and the Importance of Working Together to Innovate and Address Healthcare Disparities in Rare Disease

25 2 2021 08:00:02 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

22 2 2021 16:30:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics Announces European Commission Has Granted Orphan Designation to Sparsentan for the Treatment of IgA Nephropathy

18 2 2021 16:30:00 提供 Nasdaq GlobeNewswire